Voyageur Pharmaceuticals is moving aggressively to expand its vertically integrated North American supply chain for radiology contrast drugs.

 

The company has announced that it has engaged Fluor Corporation to lead comprehensive feasibility studies for two major infrastructure projects.

 

Fluor, a global engineering, procurement, construction and maintenance firm, will evaluate both an iodine production initiative in the United States and a large-scale integrated manufacturing facility designed to produce finished contrast media drugs.

 

The engagement includes:

 

Iodine Project in collaboration with Bayer: A feasibility study for a proposed iodine extraction and production facility in Oklahoma, USA using Voyageur's previously announced patent pending Meuller process developed in collaboration with Bayer under the milestone-based funding agreement announced on February 23, 2026. This project aims to produce high-purity iodine from iodine-rich oilfield brine for use in contrast media drugs.

 

Integrated iodine and barium contrast drug manufacturing facility: A feasibility study for the Company’s planned pharmaceutical manufacturing plant that management of Voyageur expects will produce finished barium and iodine-based contrast media products. This facility is expected to integrate Voyageur’s high-purity barite from its 100%-owned Frances Creek barium deposit in British Columbia, with domestically sourced iodine, creating the first fully integrated “Earth-to-Bottle” contrast media platform in North America.

 

Voyageur has budgeted US$2,350,000 for completion of the Bayer project feasibility study and will create a final budget for the integrated iodine and barium drug facility feasibility study, after completion of the testing of Voyageurs proprietary Streamline iodine drug manufacturing process. 

 

Fluor’s world-class expertise in process engineering, project economics, and large-scale industrial facility design will ensure both studies meet the highest technical, environmental, and economic standards required for project financing and regulatory approvals. The studies are expected to be completed in early 2027, paving the way for a potential construction decision in 2027.

 

"We are thrilled to partner with Fluor to de-risk and accelerate these projects,” said Brent Willis, CEO of Voyageur Pharmaceuticals. 

 

“These feasibility studies represent a major milestone in our strategy to become the first fully integrated producer of both barium and iodine contrast agents on the continent.”